Although it is estimated that each year 15 million people suffer from a stroke episode, due to the limited usable time frame of tissue plasminogen activator, only a small per cent of patients can actually benefit from the only treatment available (Thrift et al., 2014). This evidence concerns the gene PLAT and Stroke.